At a glance
- Originator Sankyo
- Class Antihypertensives
- Mechanism of Action Renin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 23 Jan 2017 Discontinued - Phase-I for Hypertension in Japan (PO)
- 19 Oct 2000 Suspended-I for Hypertension in Japan (PO)